LianBio (LIAN) Competitors $0.05 0.00 (-1.82%) As of 07/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendFDA EventsInsider TradesSEC FilingsTrendsBuy This Stock LIAN vs. DRUG, GALT, IMAB, TLSA, DERM, CYBN, DMAC, NVCT, PBYI, and ACRSShould you be buying LianBio stock or one of its competitors? The main competitors of LianBio include Bright Minds Biosciences (DRUG), Galectin Therapeutics (GALT), I-Mab (IMAB), Tiziana Life Sciences (TLSA), Journey Medical (DERM), Cybin (CYBN), DiaMedica Therapeutics (DMAC), Nuvectis Pharma (NVCT), Puma Biotechnology (PBYI), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. LianBio vs. Its Competitors Bright Minds Biosciences Galectin Therapeutics I-Mab Tiziana Life Sciences Journey Medical Cybin DiaMedica Therapeutics Nuvectis Pharma Puma Biotechnology Aclaris Therapeutics Bright Minds Biosciences (NASDAQ:DRUG) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends. Which has preferable valuation & earnings, DRUG or LIAN? Bright Minds Biosciences is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.36-83.00LianBioN/AN/A-$110.29M-$0.81-0.07 Do insiders and institutionals believe in DRUG or LIAN? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is DRUG or LIAN more profitable? Bright Minds Biosciences' return on equity of -14.56% beat LianBio's return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -14.56% -14.29% LianBio N/A -33.17%-30.19% Does the media prefer DRUG or LIAN? In the previous week, Bright Minds Biosciences had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 0 mentions for LianBio. Bright Minds Biosciences' average media sentiment score of 0.81 beat LianBio's score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Overall Sentiment Bright Minds Biosciences Positive LianBio Neutral Which has more risk & volatility, DRUG or LIAN? Bright Minds Biosciences has a beta of -6.01, suggesting that its stock price is 701% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Do analysts prefer DRUG or LIAN? Bright Minds Biosciences presently has a consensus target price of $83.25, indicating a potential upside of 178.61%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Bright Minds Biosciences is more favorable than LianBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryBright Minds Biosciences beats LianBio on 11 of the 14 factors compared between the two stocks. Get LianBio News Delivered to You Automatically Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIAN vs. The Competition Export to ExcelMetricLianBioBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.84M$135.38M$5.57B$9.42BDividend YieldN/A3.74%4.05%3.99%P/E Ratio-0.073.7228.0920.08Price / SalesN/A4,296.05403.9184.07Price / CashN/A13.1936.1958.45Price / Book0.0242.308.615.83Net Income-$110.29M-$90.99M$3.24B$258.27M7 Day PerformanceN/A3.67%3.53%2.69%1 Month PerformanceN/A7.77%10.99%12.91%1 Year PerformanceN/A189.36%35.43%21.81% LianBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIANLianBioN/A$0.05-1.8%N/A-82.6%$5.84MN/A-0.07110DRUGBright Minds Biosciences2.4673 of 5 stars$24.36-5.0%$83.25+241.7%+2,591.9%$180.68MN/A-67.66N/ANews CoverageGALTGalectin Therapeutics2.4958 of 5 stars$2.80-1.8%$6.00+114.3%+8.9%$180.38MN/A-3.899Gap UpIMABI-Mab2.8992 of 5 stars$2.10-1.9%$6.00+185.7%+47.6%$174.75M$3.89M0.00380TLSATiziana Life Sciences1.2296 of 5 stars$1.47-0.7%N/A+97.8%$172.93MN/A0.008DERMJourney Medical1.6318 of 5 stars$6.98-5.8%$9.50+36.1%+36.6%$172.62M$56.13M-17.9090Positive NewsCYBNCybin2.7164 of 5 stars$7.46-0.1%$85.00+1,039.4%N/A$171.99MN/A-1.7050DMACDiaMedica Therapeutics1.2132 of 5 stars$4.30+7.2%$8.00+86.0%+49.7%$171.96MN/A-6.7220Positive NewsHigh Trading VolumeNVCTNuvectis Pharma2.3157 of 5 stars$8.28+0.7%$17.00+105.3%+17.0%$171.74MN/A-7.338PBYIPuma Biotechnology4.2483 of 5 stars$3.46+0.3%$7.00+102.3%-7.0%$171.23M$230.50M4.49200Upcoming EarningsACRSAclaris Therapeutics1.6905 of 5 stars$1.52-3.8%$8.71+473.3%+20.0%$171.08M$17.78M-1.09100 Related Companies and Tools Related Companies DRUG Alternatives GALT Alternatives IMAB Alternatives TLSA Alternatives DERM Alternatives CYBN Alternatives DMAC Alternatives NVCT Alternatives PBYI Alternatives ACRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIAN) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Share LianBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
